Journal of Diabetes Research / 2011 / Article / Tab 2 / Research Article
Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials Table 2 Characteristics of the studies included in the meta-analysis.
Study* (ref.) NCT/FDA-reference Add-on to Description of randomization Description of allocation Description of blinding Reporting of drop-out Intention-to-treat Albiglutide versus placebo Rosenstock et al. [19 ] NCT00518115 None/Metf. NA NA A A Yes Exenatide versus placebo Gill et al. [20 ] NCT00516074 Metf./TZD NA NA A A Yes Kadowaki et al. [21 ] NCT00382239 Sulfonylurea A NA A A Yes Zinman et al. [22 ] NCT00099320 TZD A A A A Yes Gao et al. [23 ] NCT00324363 SU + Metf. A NA A A Yes DeFronzo et al. [24 ] NCT00135330 Rosiglitazone A NA OL A Yes Apovian et al. [25 ] NR Multiple A A A A Yes Moretto et al. [26 ] NCT00381342 None A A A A Yes Liutkus et al. [27 ] NR Metf/TZD + Met A A A A Yes DeFronzo et al. [28 ] NCT00039013 Metformin A NA A A Yes Buse et al. [29 ] NCT00039026 Sulfonylurea A NA A A Yes Kendall et al. [30 ] NCT00035984 SU + Metf. NA NA A A Yes Exenatide versus rosiglitazone DeFronzo# et al. [24 ] NCT00135330 None A NA OL A Yes Exenatide versus glibenclamide Derosa et al. [31 ] NCT00135330 None A NA OL A Yes Exenatide versus BiAsp 30/70 Bergenstal et al. [32 ] NCT00097877 SU + Metf. A A OL A Yes Nauck et al. [33 ] NCT00082407 SU + Metf. A A OL A Yes Exenatide versus glargine Barnett et al. [34 ] NCT00099619 SU + Metf. A A OL A Yes NCT00360334 [35 ] NCT00360334 OAD NR NR OL A Yes Heine et al. [36 ] NCT00082381 SU + Metf. A A OL A Yes Bunck et al. [37 ] NCT00097500 Metformin A NA OL A Yes Diamant et al. [38 ] NCT00641056 SU + Metf./Metf A A OL A Yes Exenatide versus insulin Davis et al. [39 ] NCT00099333 SU/Metf. NA NA OL A Yes Exenatide LAR versus placebo Kim et al. [40 ] NCT00103935 Metf./None A A A A Yes Exenatide LAR versus pioglitazone Bergenstal et al. [41 ] NCT00637273 None A A A A Yes Exenatide LAR versus sitagliptin Bergenstal et al. [41 ]# NCT00637273 None A A A A Yes Liraglutide versus placebo Madsbad et al. [42 ] FDA_1310 None NA NA A A Yes Vilsbøll [43 ] NCT00154401 None NA NA A A Yes Seino et al. [44 ] FDA_1334 None A A A A Yes Kaku et al. [45 ] NCT00395746 Sulfonylurea NA NA NA NA Yes Russell-Jones et al. [46 ] NCT00331851 SU + Metf. A A A A Yes Zinman et al. [47 ] NCT00333151 Metf. + TZD A A A A Yes Marre et al. [48 ] NCT00318422 Sulfonylurea NA NA A A Yes Nauck et al. [49 ] NCT00318461 Metformin A A A A Yes Liraglutide versus metformin Feinglos et al. [50 ] NR None NA NA NA A No Liraglutide versus rosiglitazone Marre# et al. [48 ] NCT00318422 Sulfonylurea NA NA A A Yes Liraglutide versus glimepiride Madsbad# et al. [42 ] NR None NA NA OL A Yes NCT00614120 [35 ] NCT00614120 Metformin NR NR OL NR NR Nauck# et al. [49 ] NCT00318461 Metformin A A OL A Yes Garber et al. [51 ] NCT00294723 None A A OL A Yes Liraglutide versus glibenclamide NCT00393718 [35 ] NCT00393718 None NR NR OL NR NR Liraglutide versus sitagliptin Pratley et al. [52 ] NCT00700817 None A A OL A Yes Liraglutide versus glargine Russell-Jones# et al. [46 ] NCT00331851 SU + Metf. A A A A Yes
*All the studies are multicenter and designed as parallel series, with the exception of NCT00099619 which is a cross-over trial; # studies with multiple comparators. Metf.: metformin; NA: not adequate or not adequately reported; A: adequate; TZD: thiazolidinediones; TZD + Met.: thiazolidinediones + metformin; SU + Metf.: sulfonylureas and metformin; OL: open-label; OAD: oral antidiabetic drugs; NR: not reported; SU/Metf: sulfonylureas or metformin; LAR: long-acting release.